A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.

Breast Cancer Stage IV Clinical Trial

— Heroine01  

Official title:

This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04469127
• Other study ID #: 145358
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: September 30, 2024
• Est. completion date: August 30, 2025

Study information

• Verified date: April 2024
• Source: Advanced Imaging Projects, LLC
• Contact: Stanley Satz, Ph.D.
• Phone: 561-561 286-6842
• Email: ssatz[@]advancedimagingprojects.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at least one prior line of therapy.

Description:

This is a prospective, Phase I/II multi-center, interventional open-label study in a total of up to 100 subjects with angiogenic breast cancer. Phase I is to assess the safety and adequacy of a dose of HurlutinTM Lu-177 for up to three cycles, at 4-week intervals. It will include a dose expansion cohort of up to 20 patients. Phase II is to demonstrate the safety, dose adequacy, anti-tumor activity and efficacy of tumor targeted therapy using Lutetium-177-DOTAGA-IAC , as a second- or third-line treatment to extend survival and improve the quality of life of patients with angiogenic breast cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: August 30, 2025
• Est. primary completion date: August 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Angiogenic breast tumor by immunohistochemistry confirmation.

2. Positive scan with PET/CT imaging with 18F-FET PET/CT.

3. Tumor progression resistant or refractory to at least one prior lines of standard chemotherapy which include trastuzumab and/or Ado-trastuzumab with or without chemotherapy agents.

4. At least 18 years of age

5. The patient is able and willing to provide informed consent and to comply with the requirements of this trial protocol.

6. ECOG score =3

7. Females of childbearing potential must have a negative serum pregnancy test or have had an intervention that renders pregnancy not possible

8. Adequate organ function, defined as:

1. Absolute neutrophil count (ANC) = 1.5 x 109/mL.

2. Hemoglobin (Hb) =10 g/dl (transfusion or use of EPO is permitted).

3. Platelets > 100,000/mm3

4. Creatinine = 1.5 x upper limit of normal (ULN)

5. AST or ALT = 2.5 x ULN (or =5 x ULN in case of liver metastasis)

6. Alkaline phosphatase =2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN.

7. Total bilirubin =1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome).

9. Baseline LVEF =40% measured using echocardiogram or equilibrium isotopic ventriculography

Exclusion Criteria:

1. Previously received external beam irradiation that includes more than 30% of bone marrow

2. Previously received external beam irradiation to a field that one kidney.

3. Previously received external beam irradiation to a field that includes the only known lesion.

4. Any uncontrolled significant medical, psychiatric or surgical condition or laboratory finding that would pose a risk to subject safety or interfere with study participation or interpretation of individual subject results.

5. Nephrectomy, renal transplant or concomitant nephrotoxic therapy putting the subject at high risk of renal toxicity during the study.

6. eGFR = 50.

7. Bone metastases are the only known lesions.

8. Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result.

9. Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.).

10. Use of any other investigational therapeutic product within 30 days prior to dosing or known requirement for any other investigational agent prior to completion of all scheduled study assessments.

11. Recognized concurrent active infection.

12. Received any live (attenuated) vaccines within 30 days prior to Visit.

13. Recent or chronic treatment with medium-to-high-dose intravenous corticosteroids (methylprednisolone 60 mg/day or hydrocortisone 300 mg/day) within 8 weeks prior to Visit or oral corticosteroids of more than 20 mg prednisone (or equivalent) within 30 days prior to Visit

14. Any unresolved NCI-CTCAE Grade 2 or higher (except alopecia) from previous anti-tumour treatment and/or medical/surgical procedures/interventions.

15. Additional inclusion criterion for measure human dosimetry

1. Unable to comply with the requirements of the dosimetry imaging protocol

2. Due to potential radiation safety issues, patients with urinary drainage or diversion (e.g., in-dwelling Foley™ catheter, ureteroileostomy, etc.) will not be enrolled.

Related Conditions & MeSH terms

• Breast Cancer Stage IV
• Breast Neoplasms

Intervention

Drug:
• Lutetium-177-DOTAGA-IAC
Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.

Locations

Country	Name	City	State
India	Postgraduate Institute of Medical and Research	Chandigarh
South Africa	CM Johannesburg Academic Hospital, University of the Witwatersrand	Johannesburg

Sponsors (3)

Lead Sponsor	Collaborator
Advanced Imaging Projects, LLC	Postgraduate Institute of Medical and Research, University of Witwatersrand, South Africa

Countries where clinical trial is conducted

India,  South Africa, 

References & Publications (2)

Baum RP, Kulkarni HR, Muller D, Satz S, Danthi N, Kim YS, Brechbiel MW. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for alphavbeta3 Integrin Receptor Targeting. Cance — View Citation

Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE. Synthesis and characterization of alphavbeta(3)-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5517-22. doi: 10.1016/j.bmcl.2012.07 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Specific Aim 1	To determine the safety and tolerability of fractionated administrations of 3 cycles of Lu-177-DOTAGA-IAC administered with 4 weeks between cycles in patients with high-risk Angiogenic Breast Cancer who have progressed on, or do not tolerate, best standard-of-care treatment.; Measurements used to assess the safety, tolerability and side-effects profile will include adverse events of any grade, grade 3 and 4 adverse events, withdrawals due to adverse events and dose reductions due to adverse events. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v.5.0) will be used to evaluate AE grade.	6 months
Primary	Specific Aim 2	To determine the pharmacokinetics (PK) of Lu-177-DOTAGA-IAC. The area under the Time vs. Concentration curve for Lu-177-DOTAGA-IAC from injection to 72 h	6 months
Primary	Specific Aim 3	To determine the whole-body biodistribution of Lu-177-DOTAGA-IAC. Percent injected dose per gram of tissue (%ID)/gm of Lu-177-DOTAGA-IAC.	6 months
Primary	Specific Aim 4	To determine the radiation dosimetry of Lu-177-DOTAGA-IAC.Time points will be 0 and 120, 30 and 150, 60 and 180, or 90 and 210 min after injection.Time integrals of activity will be entered into the (Organ Level INternal Dose Assessment/ EXponential Modeling) OLINDA/EXM software.	6 months
Primary	Specific Aims 5	To determine optimum cumulative fractionated administered dose. Increase dose range if a DLT (Dose Limiting Toxicity) develops or they do not have a T/B ratio >1.	6 months
Secondary	Specific Aim 1	To determine the Objective Response Rate (ORR) of fractionated administration of Lu-177-DOTAGA-IAC.Percentage of subjects still alive. Percentage of subjects who achieved a best overall response of Complete Response [CR] or Partial Response [PR] according to RECIST 5.0 Criteria.	6-12 Months